JP2024505887A5 - - Google Patents
Info
- Publication number
- JP2024505887A5 JP2024505887A5 JP2023545274A JP2023545274A JP2024505887A5 JP 2024505887 A5 JP2024505887 A5 JP 2024505887A5 JP 2023545274 A JP2023545274 A JP 2023545274A JP 2023545274 A JP2023545274 A JP 2023545274A JP 2024505887 A5 JP2024505887 A5 JP 2024505887A5
- Authority
- JP
- Japan
- Prior art keywords
- particle according
- item
- polynucleotide sequence
- cell surface
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142347P | 2021-01-27 | 2021-01-27 | |
| US63/142,347 | 2021-01-27 | ||
| US202163185765P | 2021-05-07 | 2021-05-07 | |
| US63/185,765 | 2021-05-07 | ||
| PCT/US2022/013947 WO2022164935A1 (en) | 2021-01-27 | 2022-01-26 | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505887A JP2024505887A (ja) | 2024-02-08 |
| JP2024505887A5 true JP2024505887A5 (cg-RX-API-DMAC10.html) | 2025-01-22 |
Family
ID=80624056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023545274A Pending JP2024505887A (ja) | 2021-01-27 | 2022-01-26 | 抗cd19キメラ抗原受容体を発現する細胞を生成するためのレンチウイルス |
Country Status (10)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Car t細胞療法のための配列決定法 |
| SG11202009975TA (en) | 2018-04-12 | 2020-11-27 | Umoja Biopharma Inc | Viral vectors and packaging cell lines |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| EP4045663A2 (en) * | 2019-10-16 | 2022-08-24 | Umoja Biopharma, Inc. | Retroviral vector for univeral receptor therapy |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024044557A1 (en) * | 2022-08-23 | 2024-02-29 | The Regents Of The University Of California | Compositions and methods for targeted delivery of crispr-cas effector polypeptides |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| KR20250120449A (ko) * | 2022-11-04 | 2025-08-08 | 우모자 바이오파마 인코포레이티드 | 폴리뉴클레오티드 구축물 및 관련 바이러스 벡터 및 방법 |
| CN120457212A (zh) * | 2022-11-04 | 2025-08-08 | 优莫佳生物制药股份有限公司 | 展示融合分子的慢病毒颗粒及其用途 |
| WO2024216227A1 (en) * | 2023-04-12 | 2024-10-17 | Vyriad | Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| EP4702034A1 (en) | 2023-04-27 | 2026-03-04 | Miltenyi Biotec B.V. & Co. KG | Pseudotyped retroviral vector particle with anti-cd3 display |
| WO2024238153A1 (en) * | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025078492A1 (en) | 2023-10-13 | 2025-04-17 | Miltenyi Biotec B.V. & Co. KG | Cd3-targeted nipah-pseudotyped lentiviral vector particles |
| WO2025102013A1 (en) * | 2023-11-10 | 2025-05-15 | Vyriad | Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof |
| WO2025176853A1 (en) | 2024-02-22 | 2025-08-28 | Miltenyi Biotec B.V. & Co. KG | Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor |
| WO2025212519A1 (en) | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
| WO2026051968A1 (zh) * | 2024-09-04 | 2026-03-12 | 深圳易慕峰生物科技股份有限公司 | 一种新型病毒颗粒及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| JP3866760B2 (ja) | 1993-02-22 | 2007-01-10 | ザ ロックフェラー ユニバーシティ | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| WO2013148327A1 (en) | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Nipah virus envelope psuedotyped lentiviruses and methods of their use |
| WO2013188693A1 (en) * | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| EP3027204B1 (en) * | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| CN108884460B (zh) * | 2016-03-19 | 2023-04-28 | 埃克苏马生物技术公司 | 淋巴细胞转导及其扩增调节的方法与组合物 |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| CA3045667A1 (en) | 2016-12-13 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| CN109535257B (zh) | 2017-09-22 | 2021-05-28 | 同润生物医药(上海)有限公司 | 新型双特异性cd3/cd19多肽复合物 |
| PT3684786T (pt) | 2017-09-22 | 2024-10-30 | Centre Nat Rech Scient | Glicoproteína mutante do vírus da estomatite vesicular |
| WO2019118885A1 (en) * | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Nkg2d daric receptors |
| SG11202009975TA (en) | 2018-04-12 | 2020-11-27 | Umoja Biopharma Inc | Viral vectors and packaging cell lines |
| CA3091490A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| EP3884058A1 (en) | 2018-11-21 | 2021-09-29 | Umoja Biopharma, Inc. | Multicistronic vector for surface engineering lentiviral particles |
-
2022
- 2022-01-26 WO PCT/US2022/013947 patent/WO2022164935A1/en not_active Ceased
- 2022-01-26 EP EP22706707.1A patent/EP4284821A1/en active Pending
- 2022-01-26 BR BR112023014980A patent/BR112023014980A2/pt unknown
- 2022-01-26 KR KR1020237028818A patent/KR20230143150A/ko active Pending
- 2022-01-26 US US18/262,859 patent/US20240141375A1/en active Pending
- 2022-01-26 MX MX2023008831A patent/MX2023008831A/es unknown
- 2022-01-26 AU AU2022212952A patent/AU2022212952A1/en active Pending
- 2022-01-26 JP JP2023545274A patent/JP2024505887A/ja active Pending
- 2022-01-26 CA CA3206009A patent/CA3206009A1/en active Pending
-
2023
- 2023-07-17 IL IL304506A patent/IL304506A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| AU2018204209B2 (en) | Method and compositions for cellular immunotherapy | |
| JP2024149496A (ja) | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 | |
| Jackson et al. | Driving CAR T-cells forward | |
| JP7360174B2 (ja) | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 | |
| Hudecek et al. | Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells | |
| Nasiri et al. | T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts | |
| JP7288503B2 (ja) | 改変された抗cd19 car-t細胞 | |
| Muhammad et al. | CAR T-cells for cancer therapy | |
| Stern et al. | CAR T cell therapy progress and challenges for solid tumors | |
| CN108276493A (zh) | 一种新型嵌合抗原受体及其应用 | |
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| JP2022528030A5 (cg-RX-API-DMAC10.html) | ||
| EP3525805A1 (en) | Compositions and methods for modulating the immune system | |
| CN114437218B (zh) | 靶向cd276的嵌合抗原受体以及包含其的免疫细胞 | |
| JP2024519335A (ja) | がん免疫療法のための投薬レジメン | |
| JP2024508808A5 (cg-RX-API-DMAC10.html) | ||
| WO2018045034A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| Haist et al. | Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas | |
| KR20190104920A (ko) | 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포 | |
| CN113474012B (zh) | Epcam抗体和epcam-car-t细胞 | |
| Hayashi et al. | A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells | |
| WO2020176897A1 (en) | Chimeric antigen receptors and uses thereof | |
| CN118786142A (zh) | 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞 | |
| CN102584999A (zh) | 靶向人vegfr-1的基因工程化淋巴细胞及其制备方法和用途 |